Sign in
Taking peopleNo phase

Testing a new questionnaire for memory and thinking worries, plus computer-based brain training

Tests a new screening tool for self-noticed cognitive decline in older adults.

Key facts

Who runs it
Istituti Clinici Scientifici Maugeri SpA
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
MASCoD - Multidimensional Assessment of Subjective Cognitive Decline
Status
Recruiting
People taking part
100 people, planned
Started
2 Aug 2022
Expected to end
Aug 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • cognitive training
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults over 55 who feel their memory or thinking has got worse, with no other cognitive or nerve problem. It tests a new screening questionnaire called MASCoD and cognitive training on a tablet.

Age
Over 55 years
Sex
All sexes
Disease stage
Self-reported decline in thinking or memory, not found by tests, with no other cognitive or neurological problem.

Main reasons for not taking part

  • Serious health problems, such as severe heart or breathing problems, or cancer
  • A past diagnosis of a psychiatric disorder (DSM-5)
  • A past diagnosis of cognitive decline
  • Major problems with seeing or hearing
  • Not able to read and write

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • reported subjective cognitive decline without any other cognitive or neurological issue,
  • Italian education,
  • adult (> 55 years old),
  • understanding of research aims,
  • signed informed consent,
  • participation on a voluntary and non-payied bases

Who cannot take part

  • prior diagnosis of psychiatric disorders according to DSM-5,
  • prior diagnosis of cognitive decline,
  • serious clinical conditions (e.g. severe cardiac and respiratory problems, neoplasia)
  • relevant visuo-perceptive or hearing deficits,
  • illiteracy or relapse in illiteracy,
  • refusal to partake in the research

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Subjective cognitive decline-SCD is a subclinical cognitive impairment subjectively experienced without being detectable from a diagnostic and neuropsychological perspective. It can negatively impact on patient's frailty and quality of life and it may be prodromal to severe cognitive impairment. Currently, only a few screening tools focusing mainly on memory complaints exist.

Read full original descriptionShow less

The aim of this study is to analyze if a new screening tool called MASCoD (Multidimensional Assessment of Subjective Cognitive Decline) can detect and monitor the SCD, predicting the risk of developing severe cognitive decline over time.

Specifically, the investigators have the following aims:

primary objectives:

1. To assess the construct validity and tune the clinical cutoffs of the new instrument through the correlation of MASCoD scores with neuropsychological evaluation and brain 18F-FDG-PET. 2. To assess the clinical validity (predictive capability) of the new instrument through a classification model (dependent variable: brain 18F-FDG-PET examination; independent variable: MASCoD; control variables: gender, age and neuropsychological evaluation).

Secondary objective:

To evaluate the suitability of MASCoD as tool for the monitoring of patients over time. Specifically, the investigators want to evaluate if the MASCoD score is able to assess the effects of a cognitive treatment and, in turn, to identify outpatients who most likely will benefit from it.

After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered by means of technological devices (Neurotablet).

At T1, all outpatients (experimental group and wait list control group) will be evaluated through MASCoD and the extensive neuropsychological evaluation for the second time.

The 2 groups in the trial

  • rehabilitation groupTreatment being tested

    Outpatients undergoing neurorehabilitation through Neurotablet

    Treatment: cognitive training

  • waiting listNo study treatment, for comparison

    Outpatients not undergoing rehabilitation during the study. They will have the possibility to carry on the rehabilitation at the end of the study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Validation and Clinical Usability of a New Screening Tool: MASCoD - Multidimensional Assessment of Subjective Cognitive Decline
Plain-language title
Testing a new questionnaire for memory and thinking worries, plus computer-based brain trainingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
13 November 2026